Literature DB >> 14642788

In-depth characterization of CGRP receptors in human intracranial arteries.

Inger Jansen-Olesen1, Linda Jørgensen, Ulla Engel, Lars Edvinsson.   

Abstract

The purpose of the present study was to characterize the effects of human (h) alpha- and beta-calcitonin gene-related peptide (CGRP) on intracranial arteries from man and to investigate the presence of mRNA for the calcitonin receptor like receptor (CRLR) and the receptor activity modifying proteins (RAMPs) 1, 2 and 3, in cerebral and middle meningeal arteries with and without endothelium, in microvessels and in the endothelial cells isolated from the human basilar artery. Reverse transcriptase-polymerase chain reaction (RT-PCR) revealed the presence of CRLR, RAMP 1, RAMP 2 and RAMP 3 in cerebral and middle meningeal arteries with and without endothelium as well as in microvessels and in the endothelial cells. Human and rat alpha- and beta-CGRP, amylin, adrenomedullin and [acetamidomethyl-Cys(2,7)]human CGRP induced strong concentration-dependent relaxation of human cerebral and middle meningeal arteries. Removal of the endothelium neither changed the maximum relaxant response nor the pIC(50) values for alpha- and beta-CGRP as compared to the responses in arteries with an intact endothelium. Human alpha-CGRP-(8-37) caused a shift of h alpha- and h beta-CGRP-induced relaxations in cerebral and middle meningeal arteries. Calculation of pK(B) values revealed that h alpha-CGRP-(8-37) could not significantly discriminate between relaxations induced by h alpha-CGRP (pK(B) around 6.8) and h beta-CGRP (pK(B) around 5.4). There was no significant difference in pK(B) value of h alpha-CGRP-(8-37) on h beta-CGRP-induced relaxation of human cerebral and middle meningeal arteries with and without endothelium. In conclusion, our molecular and pharmacological data support the existence of a single type of CGRP(1) receptors in the human intracranial circulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642788     DOI: 10.1016/j.ejphar.2003.09.021

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery.

Authors:  L Edvinsson; E Nilsson; I Jansen-Olesen
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

3.  Effects of Voluntary Locomotion and Calcitonin Gene-Related Peptide on the Dynamics of Single Dural Vessels in Awake Mice.

Authors:  Yu-Rong Gao; Patrick J Drew
Journal:  J Neurosci       Date:  2016-02-24       Impact factor: 6.167

Review 4.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Effect of CGRP and sumatriptan on the BOLD response in visual cortex.

Authors:  Mohammad S Asghar; Adam E Hansen; Henrik B W Larsson; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2012-01-14       Impact factor: 7.277

6.  CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura.

Authors:  Aaron J Schain; Agustin Melo-Carrillo; Jennifer Stratton; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2019-05-24       Impact factor: 6.167

7.  AM₁-receptor-dependent protection by intermedin of human vascular and cardiac non-vascular cells from ischaemia-reperfusion injury.

Authors:  David Bell; Malcolm Campbell; Matthew Ferguson; Leah Sayers; Liz Donaghy; Anna O'Regan; Victoria Jewhurst; Mark Harbinson
Journal:  J Physiol       Date:  2011-12-19       Impact factor: 5.182

8.  HIF-1alpha subunit and vasoactive HIF-1-dependent genes are involved in carbon monoxide-induced cerebral hypoxic stress response.

Authors:  S Bani Hashemi; J Braun; W M Bernhardt; W Rascher; J Dötsch; R Trollmann
Journal:  Eur J Appl Physiol       Date:  2008-06-17       Impact factor: 3.078

Review 9.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

Review 10.  Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.

Authors:  Andrea Stephanie Link; Anikó Kuris; Lars Edvinsson
Journal:  J Headache Pain       Date:  2008-01-23       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.